Adaptive Biotechnologies Corp (ADPT) concluded trading on Wednesday at a closing price of $8.03, with 4.92 million shares of worth about $39.52 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 70.85% during that period and on March 05, 2025 the price saw a loss of about -1.11%. Currently the company’s common shares owned by public are about 147.77M shares, out of which, 143.70M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of -3.95% in past 5 days and over the past one month there was a price change of 4.29%. Year-to-date (YTD), ADPT shares are showing a performance of 33.94% which increased to 99.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $8.95 during that period. The average intraday trading volume for Adaptive Biotechnologies Corp shares is 1.41 million. The stock is currently trading -1.41% below its 20-day simple moving average (SMA20), while that difference is up 7.79% for SMA50 and it goes to 51.79% higher than SMA200.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) currently have 147.77M outstanding shares and institutions hold larger chunk of about 92.61% of that.
The stock has a current market capitalization of $1.19B and its 3Y-monthly beta is at 1.72. It has posted earnings per share of -$1.08 in the same period. It has Quick Ratio of 2.81 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADPT, volatility over the week remained 10.37% while standing at 8.81% over the month.
Stock’s fiscal year EPS is expected to rise by 14.13% while it is estimated to increase by 23.88% in next year. EPS is likely to grow at an annualized rate of 26.66% for next 5-years, compared to annual growth of -1.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on July 05, 2023 offering an Overweight rating for the stock and assigned a target price of $15 to it. Coverage by Scotiabank stated Adaptive Biotechnologies Corp (ADPT) stock as a Sector outperform in their note to investors on January 05, 2023, suggesting a price target of $15 for the stock. On December 21, 2022, Piper Sandler Upgrade their recommendations, while on August 25, 2022, Credit Suisse Initiated their ratings for the stock with a price target of $8. Stock get a Neutral rating from Piper Sandler on June 03, 2022.
